Boston Scientific Total Operating Expenses decreased by 11.9% to $2.51B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.8%, from $2.29B to $2.51B. Over 4 years (FY 2021 to FY 2025), Total Operating Expenses shows an upward trend with a 10.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Rising expenses without a corresponding rise in revenue can indicate operational bloat or aggressive expansion efforts.
The sum of all costs required to run the business that are not directly tied to production, including R&D and SG&A. It r...
Investors compare this to revenue to assess the 'operating leverage' of a business model.
total_operating_expenses| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.87B | $1.65B | $1.98B | $1.61B | $1.81B | $1.83B | $1.83B | $1.80B | $2.03B | $1.73B | $2.00B | $1.97B | $2.33B | $2.16B | $2.42B | $2.29B | $2.61B | $2.49B | $2.85B | $2.51B |
| QoQ Change | — | -12.0% | +20.1% | -18.7% | +12.8% | +1.3% | -0.2% | -1.8% | +12.9% | -14.5% | +15.1% | -1.1% | +18.1% | -7.1% | +11.8% | -5.5% | +13.9% | -4.3% | +14.4% | -11.9% |
| YoY Change | — | — | — | — | -3.2% | +11.4% | -7.3% | +12.0% | +12.0% | -5.5% | +9.0% | +9.8% | +14.9% | +24.9% | +21.3% | +16.0% | +11.8% | +15.2% | +17.9% | +9.8% |